Erin Chew

Dr. Erin Chew


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
JJJake S. Jacob
Jake S. Jacob
MLMichelle E. Lee
Michelle E. Lee
ECErin Chew
Erin Chew
ATAaron P. Thrift
Aaron P. Thrift
RSRobert J. Sealock
Robert J. Sealock
The American Society for Gastrointestinal Endoscopy (ASGE) revised its guidelines for risk stratification of patients with suspected choledocholithiasis. This study aimed to assess the diagnostic performance of the revision and to compare it to the previous guidelines. We conducted a retrospective cohort study of 267 patients with suspected choledocholithiasis. We identified high-risk patients according to the original and revised guidelines and examined the diagnostic accuracy of both guidelines. We measured the association between individual criteria and choledocholithiasis. Under the original guidelines, 165 (62%) patients met the criteria for high risk, of whom 79% had confirmed choledocholithiasis. The categorization had a sensitivity and specificity of 68% and 55%, respectively, for the detection of choledocholithiasis. Under the revised guidelines, 86 (32%) patients met the criteria for high risk, of whom 83% had choledocholithiasis. The revised categorization had a lower sensitivity and higher specificity of 37% and 80%, respectively. The positive predictive value of the high-risk categorization increased with the revision, reflecting a potential decrease in diagnostic endoscopic retrograde cholangiopancreatograpies (ERCPs). Stone visualized on imaging had the greatest specificity for choledocholithiasis. Gallstone pancreatitis was not associated with the risk for choledocholithiasis. The 2019 revision of the ASGE guidelines decreases the utilization of ERCP as a diagnostic modality and offers an improved risk stratification tool.

1 May 2017 in Oral Oncology
Verified
Journal Article
Closed access
ECErin Chew
Erin Chew
CHChristine M. Hartman
Christine M. Hartman
PRPeter A. Richardson
Peter A. Richardson
JZJose P. Zevallos
Jose P. Zevallos
ASAndrew G. Sikora
Andrew G. Sikora
ECElizabeth Chiao
Elizabeth Chiao

22 March 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MBMeridith Leigh Balbach
Meridith Leigh Balbach
RCRobert Corty
Robert Corty
JHJohn Bradford Hill
John Bradford Hill
TFTracy Frech
Tracy Frech
FAFawad Aslam
Fawad Aslam
ECErin Chew
Erin Chew
Hand impairment is a frequently reported complaint in systemic sclerosis (SSc) patients and a leading cause of disability and diminished quality of life. Managing hand pain can be particularly challenging due to the coexistence of non-inflammatory arthralgias, inflammatory arthritis, acro-osteolysis, tenosynovitis, joint contractures, tendon friction rubs, nerve entrapment, Raynaud’s phenomenon (RP), digital ulcers (DU), sclerodactyly, calcinosis, and chronic pain. While physical examination and radiographs are the first line methods for evaluating hand pain, they are limited in scope and miss many underlying etiologies of hand impairment. We propose a joint ultrasound (US) hand protocol to differentiate between various articular, periarticular, ischemic, skin, and nerve pathologies and to assist in targeted treatment strategies.

1 September 2021 in American Heart Journal Plus: Cardiology Research and Practice
Verified
Journal Article
Open access
BSBahadir Simsek
Bahadir Simsek
BEBugra Han Egeli
Bugra Han Egeli
ASAtakan Selte
Atakan Selte
BVBibin Varghese
Bibin Varghese
RBRoger S. Blumenthal
Roger S. Blumenthal
ECErin Chew
Erin Chew
Chronic inflammation promotes the development and progression of atherosclerosis. Despite aggressive risk reduction, patients with coronary artery disease have a significant residual risk of myocardial infarction and cardiovascular death related in part to ongoing inflammation within coronary vasculature. In this review, we summarize the clinical trials that provide evidence for the inflammatory hypothesis of atherogenesis. Additionally, we describe studies suggesting colchicine may be able to reduce residual inflammatory risk via the NLRP3 pathway. Given its tolerable side effect profile, safety, and low cost, colchicine holds promise as an anti-inflammatory agent in primary and secondary prevention of coronary disease.

29 September 2023
Verified
Book Chapter
Open access
PDF file
MFMadeleine E. Frech
Madeleine E. Frech
GAGaniat Adeogun
Ganiat Adeogun
ECErin Chew
Erin Chew
TFTracy Frech
Tracy Frech
STS Bobo Tanner
S Bobo Tanner
Bone health in systemic sclerosis (SSc) is an essential management consideration for rheumatologists caring for these patients. Screening for reduction in bone density includes a detailed health history, which includes SSc disease features such as intestinal malabsorption, patulous esophagus, and calcinosis. The established International Society for Clinical Densitometry (ISCD) guidelines provide an official position statement on important topics in skeletal assessment. Bone health laboratory testing are indicated in all SSc patients, especially if a low serum albumin or vitamin deficiencies are detected. Bone health treatment considerations include adequate weight bearing exercise, calcium, and vitamin D in all SSc patients. The key findings of this chapter is that SSc patients are at increased risk for low bone density and comorbidities may affect choice of treatment such as oral bisphosphonates in SSc patients with significant esophageal disease or renal impairment and osteoanabolic therapies in SSc patients with calcinosis are important.

15 February 2024 in JBMR Plus
Verified
Journal Article
Open access
PDF file
MBMeridith L Balbach
Meridith L Balbach
JHJennifer R Hewlett
Jennifer R Hewlett
RWRobert A Wermers
Robert A Wermers
KWKenneth J Warrington
Kenneth J Warrington
STS Bobo Tanner
S Bobo Tanner
ECErin Chew
Erin Chew
Bisphosphonates frequently provoke a cytokine-driven acute clinical response (ACR) characterized by fever, chills, arthralgias, and myalgias. More rarely, an association between aminobisphosphonates, such as alendronate and zoledronic acid, and rheumatologic and/or immune-mediated syndromes (RIMS) has been described. Herein we report 2 patients, one with a prior history of rheumatic disease and one without, who developed giant cell arteritis meeting the American College of Rheumatology 2022 criteria following zoledronic acid infusion. We subsequently review existing mechanistic and clinical literature supporting this link. The duration of symptoms and elevation of inflammatory markers may serve as indicators for differentiating between the more common ACR and less frequent but potentially morbid RIMS. Although the benefit of bisphosphonates will outweigh the risk of RIMS for most patients with high fracture risk, clinicians should be aware of this phenomenon to assist earlier diagnosis and treatment in affected individuals.